Zoladex (Breast cancer) report

棋牌游戏网站

2018-10-10

::::(ExcludingStage0)(MBC):Adjuvant,::BreastCancer,IncidencesandMortality,ByCountry,2008-20305Table2:BreastCancer,Global,MarketSizeForecasts($bn),201020208Table3:Five-YearRelativeSurvivalRates,ByStages14Table4:DrugRiskBenefitScoreofZoladex30Table5:Zoladex,BreastCancer,Global,SalesForecasts($m),2002202034Table6:Zoladex,BreastCancer,TheUS,SalesForecasts($m),2002202035Table7:Zoladex,BreastCancer,TheUK,SalesForecasts($m),2002202036Table8:Zoladex,BreastCancer,France,SalesForecasts($m),2002202037Table9:Zoladex,BreastCancer,Germany,SalesForecasts($m),2002202038Table10:Zoladex,BreastCancer,Italy,SalesForecasts($m),2002202039Table11:Zoladex,BreastCancer,Spain,SalesForecasts($m),2002202040Table12:Zoladex,BreastCancer,Japan,SalesForecasts($m),:DistributionbyIncidenceandMortality,MostCommonlyDiagnosedCancers,Global,20106Figure2:BreastCancer,Global,MarketSizeForecasts($bn),201020208Figure3:TopTenMostFrequentCancersonIncidence-MortalityMatrix,Worldwide,20109Figure4:Incidenceper100,000,BreastCancer,SelectedCountries,1975-200510Figure5:Incidenceper100,000,BreastCancer,SelectedCountries,1975-200510Figure6:BreastCancer,Incidence,Worldwide,2008-203011Figure7:AllCancers,Incidence,Worldwide,2008-203011Figure8:Mortalityper100,000,BreastCancer,SelectedCountries,1975-200512Figure9:Mortalityper100,000,BreastCancer,SelectedCountries,1975-200512Figure10:BreastCancer,Mortality,Worldwide,2008-203013Figure11:AllCancers,Mortality,Worldwide,2008-203013Figure12:BroadClassificationofBreastCancer,ByType15Figure13:ClassificationofNon-InvasiveBreastCancer,ByCIS15Figure14:ClassificationofInvasiveBreastCancer,ByStages16Figure15:ClassificationofInvasiveBreastCancer,ByTreatment16Figure16:ClassificationofMetastaticorAdvancedBreastCancer16Figure17:ClassificationofEarlyStageBreastCancer(ExcludingStage0)17Figure18:ClassificationofLocallyAdvancedBreastCancer17Figure19:MetastaticBreastCancerClassification17Figure20:CurrentMolecularBiomarkersusedintheClinicalManagementofBreastCancer18Figure21:BreastCancerIntrinsicSubTypesusedforDecidingTreatmentOptionsforMBC19Figure22:BreastCancerTypesinDecreasingOrderoftheirAggressiveness19Figure23:TreatmentOptions,DCISBreastCancer20Figure24:TreatmentOptions,LCISBreastCancer21Figure25:TreatmentOptions,StagesI,IIandIIIA21Figure26:TreatmentOptions,StagesI,IIandIIIA(HRPositiveandPremenopausalBreastCancer)22Figure27:TreatmentOptions,StagesI,IIandIIIA(HRNegative,PreandPostmenopausalBreastCancer)22Figure28:TreatmentOptions,StagesI,IIandIIIA(HRPositivePostmenopausalBreastCancer)23Figure29:AdjuvantTherapyforHRPositive,HER2NegativeMetastaticBreastCancer24Figure30:HormonalTherapyinAdjuvantSettinginHRPositive,HER2NegativeMBC24Figure31:AdjuvantandFirstLineTherapyforHRNegative,HER2NegativeMetastaticBreastCancer26Figure32:TreatmentOptions,HRNegativeandHER2PositiveMetastaticBreastCancer27Figure33:DrugModelDiagramofZoladex32Figure34:Zoladex,BreastCancer,Global,SalesForecasts($m),2002202034Figure35:Zoladex,BreastCancer,TheUS,SalesForecasts($m),2002202035Figure36:Zoladex,BreastCancer,TheUK,SalesForecasts($m),2002202036Figure37:Zoladex,BreastCancer,France,SalesForecasts($m),2002202037Figure38:Zoladex,BreastCancer,Germany,SalesForecasts($m),2002202038Figure39:Zoladex,BreastCancer,Italy,SalesForecasts($m),2002202039Figure40:Zoladex,BreastCancer,Spain,SalesForecasts($m),2002202040Figure41:Zoladex,BreastCancer,Japan,SalesForecasts($m),2002202041Figure42:Zoladex,BreastCancer,SalesForecastsbyCountry($m),202042Figure43:DrugModelDiagram45Figure44:PatientsApprovedfortheDrug46NO:12-12。